Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Rhythm Pharmaceuticals is a rare disease biotech commercializing setmelanotide (IMCIVREE), an MC4R agonist approved for genetic obesity disorders including POMC, PCSK1, and LEPR deficiencies, plus Bardet-Biedl syndrome. The company operates in ultra-orphan indications with ~2,000-3,000 addressable patients globally, leveraging high pricing ($350K+ annual treatment cost) and minimal competition in melanocortin pathway disorders. Stock trades on commercial execution, label expansion potential, and path to profitability as the rare obesity franchise scales.
Rhythm generates revenue through ultra-high-priced ($350K-400K annually per patient) orphan drug sales targeting genetically validated obesity disorders with no alternative therapies. Pricing power stems from life-altering efficacy (30-50% weight loss in responders), orphan drug exclusivity through 2027-2032 depending on indication, and payer willingness to cover rare genetic diseases. The company sells through specialty pharmacies and rare disease distributors, avoiding traditional sales force infrastructure. Gross margins exceed 85% due to low COGS for peptide manufacturing, with profitability dependent on reaching 400-600 commercial patients to cover $80-100M annual operating expenses. Competitive moat derives from MC4R pathway biology expertise, clinical trial infrastructure in ultra-rare populations, and regulatory precedent for genetic testing-based patient identification.
Quarterly commercial patient count and net revenue per patient (key indicators of launch trajectory and reimbursement success)
Label expansion progress for hypothalamic obesity (potential 10x market expansion to 20,000+ patients) and other MC4R pathway disorders
International reimbursement approvals in Germany, France, UK, and other EU markets (currently limited ex-US penetration)
Clinical trial readouts for pipeline indications and real-world evidence publications demonstrating durability of weight loss
Cash runway updates and path to profitability milestones (current burn rate $25-30M per quarter)
Obesity drug market disruption from GLP-1 agonists (Wegovy, Zepbound) potentially reducing payer willingness to cover ultra-high-cost genetic obesity therapies despite different mechanisms and patient populations
Genetic testing adoption barriers limiting patient identification, as diagnosis requires specialized MC4R pathway testing not routinely performed in clinical practice
Regulatory pathway uncertainty for hypothalamic obesity indication, which lacks genetic biomarker and faces higher evidence bar for approval
Novo Nordisk and Eli Lilly developing next-generation obesity therapies with potential efficacy approaching genetic obesity treatment levels at fraction of cost
Academic research into gene therapy or CRISPR approaches for genetic obesity potentially offering curative alternatives to chronic peptide therapy
Larger rare disease companies (Sarepta, BioMarin) potentially entering MC4R pathway space through acquisition or internal development
Cash burn of $100-120M annually requires path to profitability by 2027-2028 or additional financing, with equity raises highly dilutive at current $6.8B market cap on $100M revenue
Debt-to-equity of 1.01x includes convertible notes that could force dilutive conversion if stock underperforms, though current ratio of 4.75x provides near-term cushion
Revenue concentration risk with single approved product and limited pipeline diversification if setmelanotide faces safety issues or competition
low - Rare genetic disease treatment demand is non-discretionary and insulated from economic cycles. Patients with severe genetic obesity disorders require continuous therapy regardless of macroeconomic conditions. However, payer budget constraints during recessions could marginally delay coverage approvals or increase prior authorization hurdles. Revenue is more sensitive to clinical adoption rates and genetic testing penetration than GDP fluctuations.
Rising rates negatively impact valuation multiples for pre-profitable biotechs as investors discount future cash flows more heavily and rotate toward current income. Higher rates increase cost of capital for potential debt financing and make equity raises more dilutive. However, Rhythm's $320M+ cash position (4.75x current ratio) provides 3-4 year runway, reducing near-term financing pressure. Rate sensitivity is primarily valuation-driven rather than operational.
Minimal direct credit exposure as revenue comes from specialty pharmacies and government payers with strong credit profiles. No meaningful accounts receivable risk or commercial lending exposure. Indirect impact through biotech sector credit conditions affecting acquisition currency and partnership valuations.
growth - Attracts biotech growth investors focused on rare disease commercial execution and label expansion optionality. The 78% one-year return and 39x price-to-sales multiple reflect momentum-driven positioning rather than value characteristics. Negative profitability and high cash burn deter income and value investors. Institutional ownership likely concentrated among healthcare-focused funds with rare disease expertise and tolerance for binary clinical/regulatory risk.
high - Small-cap biotech with single-product revenue concentration exhibits elevated volatility. Beta likely 1.5-2.0x market given $6.8B market cap, pre-profitability status, and sensitivity to quarterly patient count beats/misses. Clinical trial readouts, reimbursement decisions, and competitive developments drive 10-20% single-day moves. Limited analyst coverage and modest trading liquidity amplify price swings.
